Lineage Cell Therapeutics (LCTX) Construction in Progress (2014 - 2019)

Lineage Cell Therapeutics' Construction in Progress history runs 6 years deep, the most recent figure standing at $8.9 million for Q1 2019.

• On a quarterly basis, Construction in Progress changed N/A year-over-year to $8.9 million in Q1 2019; TTM through Mar 2019 was $8.9 million, a N/A change from a year earlier, with the FY2018 full-year figure at $1.3 million, down 77.08% from the prior year.
• Construction in Progress improved to $8.9 million in Q1 2019 per LCTX's latest filing, from $1.3 million in the prior quarter.
• Across five years, Construction in Progress topped out at $8.9 million in Q1 2019 and bottomed at $93000.0 in Q4 2015.
• The 5-year median for Construction in Progress is $1.6 million (2016), against an average of $3.1 million.
• Across the five-year window, Construction in Progress sank 77.09% in 2015 and surged 117.26% in 2016, its largest moves.
• Year by year, Construction in Progress stood at $93000.0 in 2015, then soared by 1620.43% to $1.6 million in 2016, then surged by 245.81% to $5.5 million in 2017, then tumbled by 77.08% to $1.3 million in 2018, then jumped by 603.31% to $8.9 million in 2019.
• Per Business Quant, the three latest LCTX Construction in Progress figures stand at $8.9 million (Q1 2019), $1.3 million (Q4 2018), and $5.1 million (Q3 2018).